Volume 7.33 | Aug 27

Mammary Cell News 7.33 August 27, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
In Situ Single-Cell Analysis Identifies Heterogeneity for PIK3CA Mutation and HER2 Amplification in HER2-Positive Breast Cancer
Investigators report specific-to-allele PCR–FISH, a novel method for the combined detection of single-nucleotide and copy number alterations in single cells in intact archived tissues. Using this method, they assessed the clinical impact of changes in the frequency and topology of PIK3CA mutation and HER2 amplification within HER2-positive breast cancer during neoadjuvant therapy. [Nat Genet] Abstract
Request a Copy: Breast Cancer Wallchart
PUBLICATIONS (Ranked by impact factor of the journal)

Spatiotemporal Control of Estrogen-Responsive Transcription in ERα-Positive Breast Cancer Cells
Scientists used three-dimensional interphase fluorescence in situ hybridization to decipher spatiotemporal gathering of multiple distant estrogen response elements in the nucleus. [Oncogene] Full Article

The Putative Oncogene CEP72 Inhibits the Mitotic Function of BRCA1 and Induces Chromosomal Instability
To gain insights into the mitotic role of BRCA1 in regulating microtubule assembly, scientists systematically identified proteins interacting with BRCA1 during mitosis and found the centrosomal protein Cep72 as a novel BRCA1-interacting protein. [Oncogene] Abstract

Exometabolom Analysis of Breast Cancer Cell Lines: Metabolic Signature
Researchers investigated the molecular signature of different subtypes of breast cancer cell lines and the breast epithelial cell line MCF-10A. They observed major differences of metabolite excretion pattern between the breast cancer cell lines and MCF-10A, just as well as between the different breast cancer cell lines themselves. [Sci Rep] Full Article

Investigation of VOCs Associated with Different Characteristics of Breast Cancer Cells
Scientists analyzed volatile organic compounds (VOCs) in the headspace of breast cancer cell lines in order to ascertain the potentiality of VOCs signatures in giving information about these cells and set up a new sensor system able to detect breast tumor-associated VOCs. [Sci Rep] Full Article

Mammary Stem Cells and Tumor-Initiating Cells Are More Resistant to Apoptosis and Exhibit Increased DNA Repair Activity in Response to DNA Damage
Researchers investigated the molecular and physiological consequences of DNA damage in wild-type mammary stem cells (MaSCs), p53-null MaSCs, and p53-null tumor-initiating cells. They showed that wild-type MaSCs and basal cells are more resistant to apoptosis and exhibit increased non-homologous end joining activity. [Stem Cell Rep] Full Article | Graphical Abstract

Dual EZH2 and EHMT2 Histone Methyltransferase Inhibition Increases Biological Efficacy in Breast Cancer Cells
The authors report that gene expression and inhibition of triple negative breast cancer cell growth are markedly increased when targeting both EZH2 and EHMT2, either by siRNA knockdown or pharmacological inhibition, rather than either enzyme independently. [Clin Epigenetics] Abstract

MicroRNA-148a Inhibits Migration of Breast Cancer Cells by Targeting MMP-13
Researchers investigated the role of microRNA (miR)-148a in migration of breast cancer cells as well as the underlying mechanism. miR-148a was found to inhibit the proliferation and migration of breast cancer cells. [Tumor Biol] Abstract

Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells
Scientists investigated the potential of curcumin to reduce breast cancer stem cell population for sensitizing breast cancer cells to mitomycin C both in vitro and in vivo. [PLoS One] Full Article

Thioaptamer-Conjugated CD44-Targeted Delivery System for the Treatment of Breast Cancer In Vitro and In Vivo
Investigators validated the safety and feasibility of systemic miRNA delivery to breast cancer cells by thioaptamer-polyethylene glycol-polyamidoamine/miRNA, testified its tumor targeting efficiency in vitro, and observed its biodistribution when it was administered systemically to a xenograft mouse model of breast cancer. [J Drug Target] Abstract

miR-139-5p Inhibits the Biological Function of Breast Cancer Cells by Targeting Notch1 and Mediates Chemosensitivity to Docetaxel
The authors researched the biological function of miR-139-5p and the efficacy of chemosensitivity to docetaxel. miR-139-5p was significantly down-regulated in breast cancer cells. miR-139-5p inhibited the viability of breast cancer cells. [Biochem Biophys Res Commun] Full Article


T-DM1 as a New Treatment Option for Patients with Metastatic HER2-Positive Breast Cancer in Clinical Practice
Investigators compared results of trastuzumab-emtansine (T-DM1) treatment in their clinical practice with data from Phase III clinical trials. [Anticancer Res] Abstract

Docetaxel Alone or in Combination with a Therapeutic Cancer Vaccine (PANVAC) in Patients with Metastatic Breast Cancer
Researchers determined if the treatment combination of docetaxel and PANVAC improves clinical outcomes in patients with metastatic breast cancer compared with docetaxel treatment alone. [JAMA Oncol]
| Press Release

Apply Now: Mammary Stem Cells Training Course (October 6-7, 2015) in Vancouver, Canada.
Of Mice and Women: A Comparative Tissue Biology Perspective of Breast Stem Cells and Differentiation
The authors examine the dissimilarities between mouse and human mammary tissue and suggest how these may impact stem cell studies. In addition, they consider the differences between breast ducts vs. lobules and clarify how these affect the interpretation of results in stem cell research. [J Mammary Gland Biol Neoplasia]
Full Article

Analysis of Different HER-2 Mutations in Breast Cancer Progression and Drug Resistance
The authors summarize the possible mutations and focus on human epidermal growth factor receptor (HER-2) variants’ role in breast cancer tumorigenesis. Additionally, the alteration of HER-2, as a potential mechanism of resistance to trastuzumab, is discussed. [J Cell Mol Med] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Medivation to Expand Global Oncology Franchise with the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, from BioMarin
Medivation, Inc. and BioMarin Pharmaceutical Inc. announced that they have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib, a highly-potent, orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase III study for the treatment of patients with deleterious germline BRCA1 or BRCA2 mutations and locally advanced and/or metastatic breast cancer. [BioMarin Pharmaceutical Inc.] Press Release

Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab
Syndax Pharmaceuticals, Inc. announced that it has entered into a clinical collaboration with Genentech to evaluate the safety, tolerability and preliminary efficacy of Syndax’s entinostat, an oral small molecule that targets immune regulatory cells, in combination with Genentech’s atezolizumab a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1, in patients with triple-negative breast cancer. [Syndax Pharmaceuticals, Inc.] Press Release

Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2 Metastatic Breast Cancer
Pfizer Inc. announced that the European Medicines Agency has validated for review the Marketing Authorization Application for IBRANCE® in combination with endocrine therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2) advanced or metastatic breast cancer. [Pfizer Inc.] Press Release

NIH Awards Nearly $34 Million to UAB Center for Clinical and Translational Science
The National Institutes of Health (NIH) has awarded the University of Alabama at Birmingham (UAB) Center for Clinical and Translational Science $33.59 million over four years to continue the center’s programs advancing translational research. [University of Alabama at Birmingham] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUOR™ can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Stem Cells: From Basic Biology to Disease Therapy
October 19-22, 2015
Suzhou, China

NEW War on Cancer 2015
October 20, 2015
London, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Research Fellow – Metastatic Breast Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Proteomic, Glycomic and Autoantibody Biomarkers of Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Cancer Biology (National Cancer Institute)

Postdoctoral Researcher – Translational Breast Cancer Research (Dublin City University)

Postdoctoral Position – Cancer Biology (Northwestern University)

Postdoctoral Position – Inflammation & Breast Tumor Metastasis (Stephenson Cancer Center)

Postdoctoral Fellow – Cancer Research (National University of Singapore)

Postdoctoral Research Fellow (Fred Hutchinson Cancer Research Center)

Research Associate/Assistant Professor – Breast Cancer (University of Chicago)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us